TrivarX Limited ( (AU:TRI) ) just unveiled an announcement.
TrivarX Limited has secured $2.25 million in funding from institutional and sophisticated investors to support a clinical trial with the US Department of Veterans Affairs and ongoing research and development initiatives. The trial aims to validate TrivarX’s single-channel mental health screening algorithm, which uses heart rate data to detect major depressive episodes. This initiative is expected to enhance the commercial viability of the company’s technology and strengthen its position in the mental health screening market.
More about TrivarX Limited
TrivarX Limited operates in the healthcare industry, focusing on mental health screening technology. The company is known for its single-channel ECG algorithm used for mental health assessments, particularly in detecting major depressive episodes. TrivarX collaborates with organizations like the Greater Los Angeles Research and Education Foundation and the US Department of Veterans Affairs to advance its research and development initiatives.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.43M
For a thorough assessment of TRI stock, go to TipRanks’ Stock Analysis page.